Log In
BCIQ
Print this Print this
 

GVXN SD133

  Manage Alerts
Collapse Summary General Information
Company GlaxoSmithKline plc
DescriptionBioconjugate vaccine against Shigella dysenteriae
Molecular Target
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine: DNA vaccine
Latest Stage of DevelopmentPhase I
Standard Indication Gastrointestinal (unspecified)
Indication DetailsVaccinate against Shigella dysenteriae infection
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today